SPIRIT FIRST
This article was originally published in The Gray Sheet
Executive Summary
First patient receives Guidant's Multi-Link Vision everolimus-eluting stent in prospective, randomized, single-blind, 60-subject feasibility study. Conducted at four sites in The Netherlands and Germany, the trial will compare in-stent late loss with the uncoated Multi-Link Vision at six months (1"The Gray Sheet" Nov. 24, 2003, p. 9)...
You may also be interested in...
Guidant DES Strategy Will Be Guided By Bare-Metal Stent Experience
Guidant will support its initial drug-eluting stent PMA submission with the 975-patient FUTURE IV randomized, pivotal trial, slated to begin at up to 70 sites in the second quarter of 2004
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.